DOI QR코드

DOI QR Code

Novel Application of Quantitative Single-Photon Emission Computed Tomography/Computed Tomography to Predict Early Response to Methimazole in Graves' Disease

  • Kim, Hyun Joo (Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Bang, Ji-In (Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Kim, Ji-Young (Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Moon, Jae Hoon (Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • So, Young (Department of Nuclear Medicine, Konkuk University Medical Center) ;
  • Lee, Won Woo (Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine)
  • Received : 2016.12.05
  • Accepted : 2017.02.01
  • Published : 2017.06.01

Abstract

Objective: Since Graves' disease (GD) is resistant to antithyroid drugs (ATDs), an accurate quantitative thyroid function measurement is required for the prediction of early responses to ATD. Quantitative parameters derived from the novel technology, single-photon emission computed tomography/computed tomography (SPECT/CT), were investigated for the prediction of achievement of euthyroidism after methimazole (MMI) treatment in GD. Materials and Methods: A total of 36 GD patients (10 males, 26 females; mean age, $45.3{\pm}13.8years$) were enrolled for this study, from April 2015 to January 2016. They underwent quantitative thyroid SPECT/CT 20 minutes post-injection of $^{99m}Tc$-pertechnetate (5 mCi). Association between the time to biochemical euthyroidism after MMI treatment and %uptake, standardized uptake value (SUV), functional thyroid mass (SUVmean ${\times}$ thyroid volume) from the SPECT/CT, and clinical/biochemical variables, were investigated. Results: GD patients had a significantly greater %uptake ($6.9{\pm}6.4%$) than historical control euthyroid patients (n = 20, $0.8{\pm}0.5%$, p < 0.001) from the same quantitative SPECT/CT protocol. Euthyroidism was achieved in 14 patients at $156{\pm}62days$ post-MMI treatment, but 22 patients had still not achieved euthyroidism by the last follow-up time-point ($208{\pm}80days$). In the univariate Cox regression analysis, the initial MMI dose (p = 0.014), %uptake (p = 0.015), and functional thyroid mass (p = 0.016) were significant predictors of euthyroidism in response to MMI treatment. However, only %uptake remained significant in a multivariate Cox regression analysis (p = 0.034). A %uptake cutoff of 5.0% dichotomized the faster responding versus the slower responding GD patients (p = 0.006). Conclusion: A novel parameter of thyroid %uptake from quantitative SPECT/CT is a predictive indicator of an early response to MMI in GD patients.

Keywords

Acknowledgement

Supported by : National Research Foundation of Korea, Seoul National University Bundang Hospital

References

  1. Brent GA. Clinical practice. Graves' disease. N Engl J Med 2008;358:2594-2605 https://doi.org/10.1056/NEJMcp0801880
  2. Bahn Chair RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 2011;21:593-646 https://doi.org/10.1089/thy.2010.0417
  3. Torring O, Tallstedt L, Wallin G, Lundell G, Ljunggren JG, Taube A, et al. Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine--a prospective, randomized study. Thyroid Study Group. J Clin Endocrinol Metab 1996;81:2986-2993
  4. Burch HB, Cooper DS. Management of Graves disease: a review. JAMA 2015;314:2544-2554 https://doi.org/10.1001/jama.2015.16535
  5. Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, et al. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid 1997;7:369-375 https://doi.org/10.1089/thy.1997.7.369
  6. Allahabadia A, Daykin J, Holder RL, Sheppard MC, Gough SC, Franklyn JA. Age and gender predict the outcome of treatment for Graves' hyperthyroidism. J Clin Endocrinol Metab 2000;85:1038-1042
  7. Abraham P, Avenell A, Park CM, Watson WA, Bevan JS. A systematic review of drug therapy for Graves' hyperthyroidism. Eur J Endocrinol 2005;153:489-498 https://doi.org/10.1530/eje.1.01993
  8. Benker G, Vitti P, Kahaly G, Raue F, Tegler L, Hirche H, et al. Response to methimazole in Graves' disease. The European Multicenter Study Group. Clin Endocrinol (Oxf) 1995;43:257-263 https://doi.org/10.1111/j.1365-2265.1995.tb02030.x
  9. Madec AM, Laurent MC, Lorcy Y, Le Guerrier AM, Rostagnat- Stefanutti A, Orgiazzi J, et al. Thyroid stimulating antibodies: an aid to the strategy of treatment of Graves' disease? Clin Endocrinol (Oxf) 1984;21:247-255 https://doi.org/10.1111/j.1365-2265.1984.tb03466.x
  10. Glinoer D, de Nayer P, Bex M; Belgian Collaborative Study Group on Graves' Disease. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study. Eur J Endocrinol 2001;144:475-483 https://doi.org/10.1530/eje.0.1440475
  11. Lee H, Kim JH, Kang YK, Moon JH, So Y, Lee WW. Quantitative single-photon emission computed tomography/computed tomography for technetium pertechnetate thyroid uptake measurement. Medicine (Baltimore) 2016;95:e4170 https://doi.org/10.1097/MD.0000000000004170
  12. Cooper DS. Antithyroid drugs. N Engl J Med 2005;352:905-917 https://doi.org/10.1056/NEJMra042972
  13. Mazza E, Carlini M, Flecchia D, Blatto A, Zuccarini O, Gamba S, et al. Long-term follow-up of patients with hyperthyroidism due to Graves' disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study. J Endocrinol Invest 2008;31:866-872 https://doi.org/10.1007/BF03346433
  14. Meller J, Becker W. The continuing importance of thyroid scintigraphy in the era of high-resolution ultrasound. Eur J Nucl Med Mol Imaging 2002;29 Suppl 2:S425-S438 https://doi.org/10.1007/s00259-002-0811-8
  15. Chang KJ, Lim I, Park JY, Jo AR, Kong CB, Song WS, et al. The role of (18)F-FDG PET/CT as a prognostic factor in patients with synovial sarcoma. Nucl Med Mol Imaging 2015;49:33-41 https://doi.org/10.1007/s13139-014-0301-5
  16. Park S, Lee E, Rhee S, Cho J, Choi S, Lee S, et al. Correlation between semi-quantitative (18)F-FDG PET/CT parameters and Ki-67 expression in small cell lung cancer. Nucl Med Mol Imaging 2016;50:24-30 https://doi.org/10.1007/s13139-015-0363-z
  17. Shimmins JG, Harden RM, Alexander WD. Loss of pertechnetate from the human thyroid. J Nucl Med 1969;10:637-640
  18. Atkins HL, Richards P. Assessment of thyroid function and anatomy with technetium-99m as pertechnetate. J Nucl Med 1968;9:7-15
  19. Lucas KJ. Use of thyroid ultrasound volume in calculating radioactive iodine dose in hyperthyroidism. Thyroid 2000;10:151-155 https://doi.org/10.1089/thy.2000.10.151
  20. Berghout A, Wiersinga WM, Smits NJ, Touber JL. Determinants of thyroid volume as measured by ultrasonography in healthy adults in a non-iodine deficient area. Clin Endocrinol (Oxf) 1987;26:273-280 https://doi.org/10.1111/j.1365-2265.1987.tb00784.x
  21. Zantut-Wittmann DE, Ramos CD, Santos AO, Lima MM, Panzan AD, Facuri FV, et al. High pre-therapy [99mTc]pertechnetate thyroid uptake, thyroid size and thyrostatic drugs: predictive factors of failure in [131I]iodide therapy in Graves' disease. Nucl Med Commun 2005;26:957-963 https://doi.org/10.1097/01.mnm.0000183795.59097.42
  22. El-Kareem MA, Derwish WA, Moustafa HM. Response rate and factors affecting the outcome of a fixed dose of RAI-131 therapy in Graves' disease: a 10-year Egyptian experience. Nucl Med Commun 2014;35:900-907 https://doi.org/10.1097/MNM.0000000000000152
  23. Atkins HL, Fleay RF. Data blending with 99mTc in evaluating thyroid anatomy by scintillation scanning. J Nucl Med 1968;9:66-73
  24. Lee WW, Lee B, Kim SJ, Jin J, Moon DH, Lee H. Kinetics of iodide uptake and efflux in various human thyroid cancer cells by expressing sodium iodide symporter gene via a recombinant adenovirus. Oncol Rep 2003;10:845-849
  25. Alexander EK, Larsen PR. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab 2002;87:1073-1077
  26. Silberstein EB, Alavi A, Balon HR, Clarke SE, Divgi C, Gelfand MJ, et al. The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med 2012;53:1633-1651 https://doi.org/10.2967/jnumed.112.105148
  27. Ritt P, Vija H, Hornegger J, Kuwert T. Absolute quantification in SPECT. Eur J Nucl Med Mol Imaging 2011;38 Suppl 1:S69-S77 https://doi.org/10.1007/s00259-011-1770-8
  28. Bailey DL, Willowson KP. An evidence-based review of quantitative SPECT imaging and potential clinical applications. J Nucl Med 2013;54:83-89 https://doi.org/10.2967/jnumed.112.111476
  29. Cachovan M, Vija AH, Hornegger J, Kuwert T. Quantification of 99mTc-DPD concentration in the lumbar spine with SPECT/CT. EJNMMI Res 2013;3:45 https://doi.org/10.1186/2191-219X-3-45
  30. Suh MS, Lee WW, Kim YK, Yun PY, Kim SE. Maximum standardized uptake value of (99m)Tc hydroxymethylene diphosphonate SPECT/CT for the evaluation of temporomandibular joint disorder. Radiology 2016;280:890-896 https://doi.org/10.1148/radiol.2016152294
  31. Walter MA, Christ-Crain M, Eckard B, Schindler C, Nitzsche EU, Muller-Brand J, et al. Radioiodine therapy in hyperthyroidism: inverse correlation of pretherapeutic iodine uptake level and post-therapeutic outcome. Eur J Clin Invest 2004;34:365-370 https://doi.org/10.1111/j.1365-2362.2004.01349.x
  32. Kristoffersen US, Hesse B, Rasmussen AK, Kjaer A. Radioiodine therapy in hyperthyroid disease: poorer outcome in patients with high 24 hours radioiodine uptake. Clin Physiol Funct Imaging 2006;26:167-170 https://doi.org/10.1111/j.1475-097X.2006.00666.x
  33. Damle N, Bal C, Kumar P, Reddy R, Virkar D. The predictive role of 24h RAIU with respect to the outcome of low fixed dose radioiodine therapy in patients with diffuse toxic goiter. Hormones (Athens) 2012;11:451-457 https://doi.org/10.14310/horm.2002.1377
  34. Glaser NS, Styne DM; Organization of Pediatric Endocrinologists of Northern California Collaborative Graves' Disease Study Group. Predicting the likelihood of remission in children with Graves' disease: a prospective, multicenter study. Pediatrics 2008;121:e481-e488 https://doi.org/10.1542/peds.2007-1535
  35. Kaguelidou F, Alberti C, Castanet M, Guitteny MA, Czernichow P, Leger J, et al. Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J Clin Endocrinol Metab 2008;93:3817-3826 https://doi.org/10.1210/jc.2008-0842

Cited by

  1. 6. Quantitative Evaluation of the Bone Scintigraphy in the Prostate Cancer vol.73, pp.10, 2017, https://doi.org/10.6009/jjrt.2017_jsrt_73.10.1087
  2. RE: Novel Application of Quantitative Single-Photon Emission Computed Tomography/Computed Tomography to Predict Early Response to Methimazole in Graves' Disease vol.19, pp.1, 2017, https://doi.org/10.3348/kjr.2018.19.1.185
  3. Utility of Quantitative Parameters from Single-Photon Emission Computed Tomography/Computed Tomography in Patients with Destructive Thyroiditis vol.19, pp.3, 2018, https://doi.org/10.3348/kjr.2018.19.3.470
  4. Age of Data in Contemporary Research Articles Published in Representative General Radiology Journals vol.19, pp.6, 2018, https://doi.org/10.3348/kjr.2018.19.6.1172
  5. Dual time-point quantitative SPECT-CT parathyroid imaging using a single computed tomography: feasibility and operator variability vol.39, pp.1, 2018, https://doi.org/10.1097/mnm.0000000000000761
  6. Quantitative Single-Photon Emission Computed Tomography/Computed Tomography for Evaluation of Salivary Gland Dysfunction in Sjögren’s Syndrome Patients vol.52, pp.5, 2017, https://doi.org/10.1007/s13139-018-0547-4
  7. Evaluation of Hot Nodules of Thyroid Gland Using Tc-99m Pertechnetate: a Novel Approach Using Quantitative Single-Photon Emission Computed Tomography/Computed Tomography vol.52, pp.6, 2017, https://doi.org/10.1007/s13139-018-0554-5
  8. A Glimpse on Trends and Characteristics of Recent Articles Published in the Korean Journal of Radiology vol.20, pp.12, 2019, https://doi.org/10.3348/kjr.2019.0928
  9. Maximum standardized uptake value of foot SPECT/CT using Tc-99m HDP in patients with accessory navicular bone as a predictor of surgical treatment vol.98, pp.2, 2017, https://doi.org/10.1097/md.0000000000014022
  10. Standardized Uptake Value Using Thyroid Quantitative SPECT/CT for the Diagnosis and Evaluation of Graves' Disease: A Prospective Multicenter Study vol.2019, pp.None, 2017, https://doi.org/10.1155/2019/7589853
  11. Clinical Applications of Technetium-99m Quantitative Single-Photon Emission Computed Tomography/Computed Tomography vol.53, pp.3, 2017, https://doi.org/10.1007/s13139-019-00588-9
  12. A Weighted Genetic Risk Score Using Known Susceptibility Variants to Predict Graves Disease Risk vol.104, pp.6, 2019, https://doi.org/10.1210/jc.2018-01551
  13. Minimum Standardized Uptake Value from Quantitative Bone Single-Photon Emission Computed Tomography/Computed Tomography for Evaluation of Femoral Head Viability in Patients with Femoral Neck Fracture vol.53, pp.4, 2017, https://doi.org/10.1007/s13139-019-00600-2
  14. Characteristics of Recent Articles Published in the Korean Journal of Radiology Based on the Citation Frequency vol.21, pp.12, 2020, https://doi.org/10.3348/kjr.2020.1322
  15. The paths of Graves’ disease in the 21st century: precision medicine is closer vol.64, pp.5, 2017, https://doi.org/10.20945/2359-3997000000304
  16. A retrospective multicenter study of quantitative bone SPECT/CT to predict the surgical removal of the accessory navicular bone vol.42, pp.9, 2021, https://doi.org/10.1097/mnm.0000000000001433
  17. Quantitative salivary gland SPECT/CT using deep convolutional neural networks vol.11, pp.1, 2017, https://doi.org/10.1038/s41598-021-87497-0